Hirasawa A., et al. 2013 |
Japan |
Retrospective |
Gynecologic
cancer
|
53 |
Irinotecan +
Cisplatin or Irinotecan alone |
60/(days 1, 8 and 15 every 4 weeks) or
100/(days 1, 8 and 15 every 4 weeks) |
Neutropenia, Diarrhea |
Invader
UGT1A1 Molecular Assay kit |
Ando K., et al. 2017 |
Japan |
Prospective |
Colorectal cancer |
35 |
XELIRI |
200/biweekly |
Neutropenia, Diarrhea |
N/A |
Atasilp C., et al. 2015 |
Thailand |
Retrospective |
Colorectal cancer |
44 |
FOLFIRI or FOLFIRI + cetuximab or FOLFIRI + bevacizumab or Modified
FOLFIRI or Single irinotecan or Irinotecan + cetuximab/capecitabine |
180/biweekly, 100/day 1 |
Neutropenia |
Pyrosequencing |
Atasilp C., et al. 2020 |
Thailand |
Retrospective and Prospective |
Colorectal cancer |
66 |
FOLFIRI or FOLFIRI + Cetuximab or FOLFIRI +
Bevacizumab or Modified FOLFIRI or Single irinotecan or Irinotecan +
Cetuximab or Irinotecan + capecitabine |
180/biweekly or 180/every 3
weeks or 100/(day 1) |
Neutropenia |
Pyrosequencing, Real-time
PCR |
Bai Y., et al. 2017 |
China |
Retrospective |
Lung
cancer, Colorectal cancer, E
sophageal cancer
|
81 |
Single irinotecan or irinotecan + cisplatin or irinotecan + bevacizumab
or irinotecan + cisplatin + bevacizumab or FOLFIRI or FOLFIRI +
bevacizumab/cetuximb |
60 (days 1, 8 and 15 for every 4 weeks) or 130
(day 1 for every 3 weeks) or 180/biweekly or 180 (day 1 for every 3
weeks) or 150/biweekly |
Neutropenia, Diarrhea |
DFMH using fluorescent
probes |
Bandyopadhyay A et al. 2021 |
India |
observational cohort |
Small cell lung cancer (SCLC)
cell lung
cancer
|
213 |
Irinotecan + cisplatin |
100 (day 1 of a 3-week cycle)
or 65(days 1 and 8 of a 3-week cycle) |
Neutropenia, Diarrhea |
polymerase chain reaction
(PCR)–
restriction fragment length polymorphism
(RFLP)
|
Chen Yang., et al. 2015 |
China |
Retrospective |
Pancreatic cancer |
48 |
FOLFIRI |
180/biweekly |
Neutropenia |
Direct
sequencing |
Choi YH., et al. 2012 |
Korea |
Retrospective |
Colorectal cancer |
29 |
CPT-11 + S-1 |
225/every 3 weeks |
Neutropenia, Diarrhea |
Direct
sequencing |
Chun-Yu Liu., et al. 2007 |
China |
Retrospective |
Colorectal cancer |
128 |
FOLFIRI |
180/biweekly |
Neutropenia, Diarrhea |
Direct
sequencing |
Deng B., et al. 2017 |
China |
Retrospective |
Malignant
tumor
|
115 |
FOLFIRI |
180/biweekly |
Neutropenia, Diarrhea |
Direct sequencing |
Gao J., et al. 2013 |
China |
Retrospective |
Gastric cancer, Esophageal
cancer |
133 |
Irinotecan + cisplatin or FOLFIRI or single irinotecan or
irinotecan + cetuximab |
180 mg/m2 |
Neutropenia |
Direct
sequencing |
Gao J., et al. 2013 |
China |
Retrospective |
Colorectal cancer |
276 |
FOLFIRI or single irinotecan or irinotecan + capecitabine |
180 mg/m2 |
Neutropenia, Diarrhea |
Direct sequencing |
Han JY., et al. 2007 |
Korea |
Prospective |
Non-Small Cell Lung Cancer |
107 |
Single irinotecan or irinotecan + cisplatin |
65 or 80/every 3
weeks |
Neutropenia and Diarrhea |
Sequencing |
Han JY., et al. 2009 |
Korea |
Prospective |
Non-Small Cell Lung Cancer |
107 |
Single irinotecan or irinotecan + cisplatin |
65 or 80/every 3
weeks |
Neutropenia and Diarrhea |
Sequencing |
Hironobu Minami., et al. 2006 |
Japan |
Retrospective |
Lung, Colon,
Stomach and others |
55 |
Single irinotecan |
100/weekly |
Neutropenia |
Pyrosequencing |
|
|
|
|
62 |
Irinotecan + Cisplatin |
150/biweekly |
|
|
|
|
|
|
103 |
IROX |
200/every 3 weeks |
|
|
Horikawa N., et al. 2015 |
Japan |
Retrospective |
Cervical cancer |
23 |
CPT-11 + Nedaplatin (NDP) every 3 weeks |
60 (day 1 and 8) |
Neutropenia, Diarrhea |
Direct sequencing |
Kimura K., et al. 2018 |
Japan |
Retrospective |
Rectal cancer |
46 |
Irinotecan-based regimen |
80/day S-1 (days 1-5, 8-12, 22-26, and
29-33), 60 (days 1, 8, 22, and 29), and 45 Gy radiation (1.8 Gy/day, 5
daysper week for 5 weeks) |
Neutropenia, Diarrhea |
Invader
assay |
Liu D., et al. 2017 |
China |
Retrospective |
Colorectal cancer |
661 |
Single irinotecan or irinotecan + target treatment or irinotecan +
fluorouracil (5-Fu, Capecitabine, S-1 or tegafur) or FOLFOXIRI |
180
mg/m2 or 150 mg/m2 |
Neutropenia, Diarrhea |
Direct
sequencing |
Masahide Onoue., et al. 2009 |
Japan |
Prospective |
Lung, Gastric,
Colorectal and Others |
133 |
Single irinotecan or Irinotecan + Platinum
or Irinotecan + other anticancer agents or FOLFIRI |
<100 or
101-150 or 151-200 or >200/weekly or biweekly or every 3 or
4 weeks |
Neutropenia |
Direct sequencing |
Matsuoka et al. 2020 |
Japan |
Retrospective |
Cervical cancer |
51 |
Irinotecan + NDP |
60/(days 1 and 8) or 60/(days 1 and 15) |
Neutropenia, Diarrhea |
Direct sequencing |
Minmin Li., et al. 2014 |
China |
Retrospective |
Colorectal cancer |
167 |
FOLFIRI or Irinotecan + Cetuximab/Bevacizumab or Irinotecan +
Raltitrexed or Irinotecan + Capecitabine |
180/biweekly or 180/every 3
weeks |
Neutropenia, Diarrhea |
Pyrosequencing |
Moriya, H. et al. 2014 |
Japan |
Retrospective |
Gynecological cancer |
44 |
Irinotecan + cisplatin or Irinotecan + mitomycin C |
40-60/(days 1,
8 and 15) or 70-150/(days 1 and 15 or on days 1, 8 and 15) |
Neutropenia |
Direct sequencing |
Nakamura Y., et al. 2011 |
Japan |
Randomized phase II trial |
Non-small
Cell Lung Cancer |
77 |
Irinotecan + paclitaxel or irinotecan +
gemcitabine |
50 (days 1, 8, and 15 for every 4 weeks) or 100 (days 1
and 8 for every 3 weeks) |
Neutropenia |
Direct
sequencing |
Okuyama Y., et al. 2011 |
Japan |
Prospective |
Colorectal cancer |
39 |
FOLFIRI |
150 mg/m2 or 100 mg/m2 |
Neutropenia |
polymerase chain
reaction-restriction fragment length polymorphism |
Park SR., et al. 2010 |
Korea |
Retrospective |
Gastric cancer |
44 |
Irinotecan + oxaliplatin |
150/every 3 weeks |
Neutropenia |
Direct
sequencing |
Peng H., et al. 2017 |
China |
Retrospective |
Gastrointestinal cancer,
lung cancer |
106 |
FOLFIRI or Single irinotecan or irinotecan +
cisplatin or irinotecan + capecitabine |
180 mg/m2 or 90 mg/m2 |
Neutropenia, Diarrhea |
Direct sequencing |
Satoh T., et al. 2011 |
Japan |
Prospective |
Gastrointestinal cancer |
73 |
Single irinotecan |
150mg⁄m2 or 100 mg⁄m2 or 75 mg⁄m2 |
Neutropenia, Diarrhea |
Invader UGT1A1 Molecular Assay
kit |
Shi Y., et al. 2015 |
China |
Retrospective |
Small cell lung cancer |
29 |
Irinotecan + cisplatin |
65 mg/m2 |
Diarrhea |
Direct
sequencing |
Shaojun Chen., et al. 2020 |
China |
Retrospective |
Colorectal cancer |
86 |
FOLFIRI |
180/biweekly |
Neutropenia, Diarrhea |
Pyrosequencing |
Sunakawa Y., et al. 2010 |
Japan |
Retrospective |
Colorectal cancer |
42 |
FOLFIRI |
180/biweekly |
Neutropenia, Diarrhea |
Direct
sequencing |
Takahara N., et al. 2013 |
Japan |
Prospective |
Pancreatic cancer |
44 |
Single irinotecan |
100 (days 1, 8 and 15 for every 4 weeks) |
Neutropenia |
Direct sequencing |
Takano M., et al. 2009 |
Japan |
Prospective |
Gynecologic cancer |
30 |
Irinotecan + cispatin |
60 (day 1, 8,15 for every 4 weeks) |
Neutropenia, Diarrhea |
Invader UGT1A1
Molecular
Assay
|
T. Yamaguchi et al. 2019 |
Japan |
Retrospective |
Gastric cancer |
74 |
Irinotecan-based regimen |
150/biweekly |
Neutropenia, Diarrhea |
The
Invader® UGT1A1 Molecular Assay kit |
Wang Y et al. 2012 |
China |
Retrospective |
Colorectal cancer |
130 |
FOLFIRI or IFL |
180/biweekly or 125/every 6 weeks |
Neutropenia,
Diarrhea |
Direct sequencing |
WANG et al. 2017 |
China |
Retrospective |
Lung, Colon, Rectum,
Esophagus, Stomach and others |
206 |
Irinotecan + antitumor platinum
drugs or Irinotecan + 5-Fluorouracil or Irinotecan + Capecitabine or
Single irinotecan |
300-350/every 3 weeks or 250/every 3 weeks or
180/biweekly or 180/every 3 weeks |
Neutropenia, Diarrhea |
Direct
sequencing |
Xiao XG., et al. 2015 |
China |
Retrospective |
Extensive-stage
small-cell lung cancer (E-SCLC) |
67 |
CPT-11 + Appropriate platinum
drug (cisplatin, carboplatin, or lobaplatin) |
60 (day 1, 8,15 for every
4 weeks) or 85/every 3 weeks |
Neutropenia, Diarrhea |
Pyrosequencing |
Xu, C. et al. 2016 |
China |
Retrospective |
Colorectal cancer |
183 |
FOLFIRI or Irinotecan + Capecitabine |
150/biweekly or 150/every 3 weeks |
Neutropenia, Diarrhea |
Direct sequencing |
Xu Ma., et al. 2020 |
China |
Retrospective |
Pulmonary neuroendocrine
tumours (PNTs) |
68 |
Single irinotecan or irinotecan + cisplatin |
60
(days 1, 8 and 15 for every 4 weeks) |
Neutropenia, Diarrhea |
quantitative fluorescent polymerase chain reaction |
Xu Q, Ding YY., et al. 2015 |
China |
Retrospective |
Ovarian cancer |
89 |
Irinotecan + cisplatin |
60 (days 1 and 8 for every 3 weeks) |
Neutropenia, Diarrhea |
Pyrosequencing |
Yamamoto N., et al. 2009 |
Japan |
Prospective |
Non–Small Cell Lung
Cancer |
36 |
Single CPT-11 |
100 (days 1 and 8 for every 3 weeks) |
Neutropenia |
Direct sequencing |
Yan-Yan Lu., et al. 2014 |
China |
Retrospective |
Lung and
Gastrointestinal cancer |
89 |
Irinotecan + Cispatin, Nedaplatin,
Carboplatin or Lobaplatin; modified FOLFIRI; Irinotecan + Platinum,
Fluorouracil, Pemetrexed or Raltitrexed |
100-175/biweekly or
100-175/every 3 weeks |
Neutropenia, Diarrhea |
Direct
sequencing |
Yun F., et al. 2014 |
China |
Retrospective |
Small cell lung cancer |
31 |
Single irinotecan |
80 (days 1 and 8 for every 3 weeks) |
Neutropenia, Diarrhea |
Direct sequencing |